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Cryopreservation of Ovarian Tissue:
Opportunities Beyond Fertility
Preservation and a Positive View Into
the Future
Stine G. Kristensen* and Claus Y. Andersen
Laboratory of Reproductive Biology, Faculty of Health Science, The Juliane Marie Centre for Women, Children and
Reproduction, University Hospital of Copenhagen, University of Copenhagen, Copenhagen, Denmark
In current years, ovarian tissue cryopreservation (OTC) and transplantation is gaining
ground as a successful method of preserving fertility in young women with primarily
cancer diseases, hereby giving them a chance of becoming biological mothers later
on. However, OTC preserves more than just the reproductive potential; it restores the
ovarian endocrine function and thus the entire female reproductive cycle with natural
levels of essential hormones. In a female population with an increased prevalence in the
loss of ovarian function due to induced primary ovarian insufficiency (POI) and aging,
there is now, a need to develop new treatments and provide new opportunities to utilize
the enormous surplus of follicles that most females are born with and overcome major
health issues associated with the lack of ovarian hormones. Cell/tissue-based hormone
replacement therapy (cHRT) by the use of stored ovarian tissue could be one such
option comprising both induction of puberty in prepubertal POI girls, treatment of POI
and premature menopause, and as primary prevention at the onset of menopause. In
the current review, we explore known and entirely new applications for the potential
utilization of OTC including cHRT, social freezing, culture of immature oocytes, and a
modern ovarian resection for women with polycystic ovaries, and discuss the indications
hereof.
Keywords: ovarian tissue cryopreservation, fertility preservation, cell/tissue-based hormone replacement therapy,
induction of puberty, ovarian resection, social freezing, in vitro maturation
INTRODUCTION
The follicle constitutes the functional unit of the ovary and produces steroids and peptide
hormones to regulate the female reproductive cycle. During the follicular phase more than
90% of the available oestradiol is produced by a single selected preovulatory follicle, which
in the luteal phase is transformed to the corpus luteum that secretes progesterone in high
concentrations. The unique physical distribution of the follicular reserve within the ovary,
with the vast majority of small resting follicles located in the outer cortical region and the
growing stages of follicles located in the inner medullary region, represents a perfect opportunity
to preserve an organ function without freezing the entire organ. By isolating the cortical
region, containing 90% of the follicular reserve, human ovarian tissue has been successfully
cryopreserved for fertility preservation in young women with cancer diseases for over two
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decades. Subsequent transplantation of thawed ovarian tissue
has restored ovarian endocrine function in 95% of the patients
and resulted in the birth of over 130 children worldwide (1, 2).
Half of all the children born have been conceived by natural
conception, which highlights the exceptional ability of this
procedure to actually restore an entire organ function in contrast
to conventional fertility preserving strategies like oocyte and
embryo freezing, in which the fertility potential is fixed by the
number of oocytes retrieved and IVF is the only option to
conceive. Moreover, ovarian tissue cryopreservation (OTC) can
be performed from day to day and is therefore the only fertility
preserving strategy for girls and young women who needs to
undertake acute gonadotoxic treatment, and for prepubertal girls
who do not yet produce mature oocytes for freezing.
Primary ovarian insufficiency (POI) is defined as the cessation
of the ovarian function before the age of 40 years, and is
a common cause of infertility in women. Its incidence is
estimated to be as high as 1 in 100 by the age of 40, and 1 in
1,000 by the age of 30 years (3, 4). Spontaneous POI include
genetic, autoimmunological, inflammatory, enzyme deficiency,
metabolic, or very often idiopathic causes, whereas induced POI
occurs mainly due to oncological treatment such as surgery
(bilateral oophorectomy), chemotherapy and radiotherapy (5).
POI not only interferes with a woman’s reproductive potential,
but the cessation of sex steroid production is also associated with
an increased risk of osteoporosis, cardiovascular disease, earlier
mortality, obesity, sexual dysfunction, dementia, and cognitive
decline (6–8).
Up until now fertility preservation has been the primary
goal of OTC in young girls and women diagnosed with a
malignancy or genetic disease threatening to destroy their
ovarian reserve. However, the restoration of an organ function,
the steroidogenic capacity of the transplanted ovarian tissue
and the unique access to immature oocytes from small antral
follicles have now evoked new perspectives and ideas to expand
the utilization of OTC beyond its traditional purpose of fertility
preservation for medical reasons. These novel ideas approach
a broader population of women and include utilization of
OTC for cell/tissue-based hormone replacement therapy (cHRT),
non-medical reasons, optimizing culture systems for immature
oocytes, and performing a modern ovarian resection for women
with polycystic ovaries (Figure 1). This kind of ideas which are
technical possible, but not yet proven, will undoubtedly raise
controversy in the field and a plethora of questions concerning
the ethics, safety, cost-effectiveness, superiority, and implications
of the proposed procedures. In this paper, we aim to explore
known and entirely new applications for the utilization of OTC
and discuss the indications for such procedures.
CELL/TISSUE-BASED HORMONE
REPLACEMENT THERAPY (cHRT)
More efficient cancer treatments combined with a general
increase in life expectancy have led to a higher frequency of
POI in a growing population of cancer survivors and aging
women. It is widely accepted that the pillar of treatment of
POI is pharmacologic hormone replacement therapy (pHRT), at
least until the average age of natural menopause. Pharmacologic
HRT with estrogen alone or estrogen and progestogens in
combination is known to effectively compensate for the loss of
ovarian hormone production, but only when it is delivered at
an optimal dosage, frequency, and at an appropriate time (8, 9).
Unfortunately, pharmacological delivery methods of HRT are
not integrated into the hypothalamic-pituitary (HP) axis which
would facilitate feedback and regulation of dosage and timing of
circulating hormone levels. As such, pharmacological hormone
delivery results in consistently higher serum concentrations as
compared to those associated with normal functional ovaries.
New approaches using cHRT offer a potential physiological
solution to timely control of hormone delivery and the ability
to restore the functionality of the HPO axis. OTC can be used
as cHRT as thawed ovarian tissue grafted into the pelvis cavity
restores the natural hormone milieu and endocrine function of
the ovary which have been consistently documented by a rise
in estradiol and a decrease in FSH and LH levels returning to
premenopausal levels 4–5 months after transplantation leading
to cessation of menopausal symptoms and renewed menstrual
cycles in the vast majority of transplanted patients (1, 10,
11). Restored hormone production may even be the desired
effect rather than fertility restoration in some patients (10),
and a more appealing alternative to pHRT for some women.
In Denmark around a dozen young women who entered
menopause due to cancer treatment have had frozen/thawed
tissue transplanted only to become a “normal woman” again and
avoid menopause (10), The average duration of graft function
is approximately 5 years, but the function can persist for over
9 years (10), depending on the follicular density at the time
of OTC (2). The transplantation procedure may be repeated
multiple times in order to stretch the longevity of the tissue,
if sufficient amounts of ovarian tissue has been stored, hereby
extending the lifespan of ovarian endocrine activity up to 11
years or more (12, 13). If patients are merely in the need
of sex steroid production, a heterotopic graft site like the
abdominal wall or a subcutaneous site may be preferred over
an orthotopic site as it requires less invasive surgery and would
obviate the need for general anesthesia and a laparoscopic
procedure. A cHRT approach combining a heterotopic graft
site with multiple transplantations extending the longevity of
banked ovarian tissue can therefore facilitate prolonged ovarian
endocrine function and have implications way beyond fertility
preservation.
Inducing Puberty in Pre-pubertal POI Girls
Survivors of childhood cancer represent a rapidly growing
population of patients in which temporary or permanent
POI is a common side effect of the cytotoxic treatments.
In addition, POI often has a genetic background with more
than 50 genes in which mutations can be causative and
many other genes that may be implicated (14). These genes
can affect various processes such as gonadal development,
DNA replication/ meiosis and DNA repair, hormonal signaling,
immune function, and metabolism, and include conditions
like Turner syndrome, sickle cell anemia, thalassemia, and
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FIGURE 1 | Potential applications for ovarian tissue cryopreservation beyond fertility preservation in young women with cancer diseases. OTC, ovarian tissue
cryopreservation; cHRT, cell/tissue-based hormone replacement therapy; POI, premature ovarian insufficiency; PCOS, polycystic ovary syndrome.
galactosemia. These young girls often experience delayed puberty
or need pHRT to induce puberty to enable the pubertal
growth spurt as well as development of secondary sexual
characteristics. However, pharmacological delivery of increasing
doses of estrogen followed with progesterone only address
some aspects of puberty and does not completely match
the physiological complexity of the hormonal milieu during
puberty. Moreover, there is only limited data on the long-term
safety of exogenous hormones in childhood cancer survivors
and pHRT can cause potentially significant side effects (15,
16).
Cell/tissue-based HRT can therefore be an attractive approach
to provide a more physiological hormonal milieu for induction
of puberty in pre-pubertal POI girls. In 2012, Poirot and co-
workers published the first case report showing that stored
ovarian tissue from pre-pubertal girls can provide adequate
endogenous sex steroid hormone levels to induce puberty (17).
In this case, a 13-year old girl developed POI after being
treated for sickle-cell disease at the age of 10, and after
having 3 out of 23 stored ovarian pieces transplanted, she
entered puberty. A second case report was published shortly
after with another 13-year old girl who had developed POI
following treatment for Ewing sarcoma at the age of 9 (18).
In both cases, a unilateral oophorectomy was performed before
treatment and a small proportion of the frozen ovarian cortical
fragments (i.e., 10–20% of the stored tissue) were transplanted
to a heterotopic location in the former case and to the
remaining ovary in the latter. Puberty was successfully induced
in both girls although the graft function failed after nearly 2
years.
It can be discussed whether or not young girls should choose
to save their ovarian tissue for later use to achieve fertility
instead (19), but using only a small percentage (i.e., 10–20%)
of the stored tissue might be worth it for some young girls to
feel “normal” during a critical period of their emotional and
social life as the physical maturation process directly affects
body and brain to alter children’s needs, interests, and moods.
Several studies have suggested that young childhood cancer
survivors with POI face significant psychosexual dysfunction
and that the symptoms of POI could severely stunt social
growth and exacerbate anxiety and feelings of isolation (20,
21). Therefore, cHRT could potentially be beneficial in the
long run at both the physiological and psychological level, and
the preferred choice for some pre-pubertal POI girls in order
for them to experience the life of every other teenager and
becoming a woman with physiological levels of sex hormones.
However, the preferred treatment for young girls with POI
is still pHRT, as it is cheap, simple, and ready available and
does not include any surgical intervention. Moreover, the
theoretical superiority of physiological hormone levels over
the pharmacological levels for induction of puberty has not
been proven in any human clinical trials and awaits further
research.
Achieving or Postponing Natural
Menopause
One century ago the average life expectancy corresponded to
the natural age of menopause around the age of 50 years,
however, nowadays the majority of women live beyond 80 years
in many developed countries, and the demographic structure
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is changing toward an increasingly aging population in which
women will spend 30–40% of their lives being postmenopausal.
In combination with the increasing population of cancer
survivors experiencing POI these developments in society calls
for preventive strategies to alleviate and decrease short- and long-
term consequences and health risks associated with the lack of
ovarian endocrine function.
The use of pHRT has been vigorously debated for several
decades. In the 1980’s and 90’s pHRT was administered to
millions of women to relieve menopausal symptoms and by the
mid-1990s estrogen became the biggest-selling prescription drug
in the US. However, it all changed with the publication of the
results from the Women’s Health Initiative (WHI) randomized
clinical trials in 2002 (22), suggesting pHRT to cause an increased
risk of breast cancer, after which many women discontinued
pHRT or avoided starting pHRT at all ages, including before age
50 years (23, 24). One of the big misunderstandings was that the
results from the WHI studies were inappropriately extrapolated
from women in the late postmenopausal stage (aged >60 years)
to younger women in the early stage of postmenopause (50–
59 years), and even further to women experiencing premature
or early natural menopause. The WHI study was built upon
numerous observational studies and clinical trials consistently
demonstrating benefits in the prevention of chronic diseases,
which include reduced coronary heart disease (CHD) and
mortality, when pHRT was initiated near the onset of menopause
(25–30). TheWHI study was therefore designed to test the effects
of pHRT in women initiating treatment a decade or more after
menopause. This is where the “timing hypothesis” comes into
play and suggest that different clinical effects occurs if hormones
are initiated close to the onset of menopause compared with
several years later (31). Basic and animal studies together with
clinical studies have now shown that the timing of pHRT can
be crucial with respect to especially CHD, cognitive decline, and
dementia (8, 31–34). In 2005, theMulti-Institutional Research on
Alzheimer Genetic Epidemiology study showed that the risk of
dementia was reduced in women who initiated hormonal therapy
at age 50–63 years, but was not reduced in women who started
hormonal treatment at ages 64–71 or 72–99 years (35).
Reassessment of clinical trials in women initiating pHRT
close to the onset of menopause together with more recent
studies and meta-analyses now show a long list of benefits
with estrogen alone therapy, and risks are considered rare.
Beyond symptomatic relief, improvements in quality of life and
a reduction in osteoporosis, estrogen-based therapy has now
been shown to be cost-effective and have a very favorable risk–
benefit profile in healthy women under the age of 60. Specifically,
estrogen alone therapy have been shown to consistently decrease
CHD in women under 60 years of age by up to 40% and to
decrease all-cause mortality by 20–40% (36–38). Moreover, a
long-term follow up on the WHI study showed that estrogen
alone therapy resulted in a significant decrease in the total risk
of cancer by 20% in women aged 50–59 years (39).
The majority of studies show benefits with estrogen alone
rather than with estrogen plus progestogen, however, no
particular HRT regimen can currently be advocated (31).
Moreover, the use of age-appropriate estrogen doses has been
reported to be crucial to maximize cardiovascular benefits
while minimizing risk of adverse effects such as venous
thromboembolism and stroke (32). This is where cHRT comes
into the picture and we hypothesize that transplantation of
stored ovarian tissue could be used to restore endocrine ovarian
function at the onset of menopause or for women entering
menopause prematurely. In 2015, we proposed that ovarian
tissue frozen in the young years could be transplanted back
at the time of menopause to provide continued endogenous,
physiological levels of steroid production to postponemenopause
(40). A small portion of stored ovarian tissuemay be transplanted
subcutaneously during local anesthesia multiple times providing
menstrual cycles for a prolonged period, using the woman’s
own tissue and follicles to sustain menstrual cycles with natural
variations in the whole armamentarium of hormones. In this
way, natural fertility will also be avoided and prevent senior
women to conceive spontaneously. Recent animal studies have
demonstrated that supraphysiological plasma levels of estrogen
were required for pHRT to achieve benefits in bone health that
were comparable to those achieved by cHRT (using ovarian cell
constructs) at much lower plasma hormone concentrations (41).
Such studies suggest a potential benefit of physiological secreted
sex steroid hormones under the control of the HPO axis at which
effects can be obtained at lower and safer plasma levels.
In theory, cHRT using OTC at a young age could be used
as a physiological solution to prevent the massive medical
legacy of osteoporosis and menopause-related conditions in
the large population of aging women, however, currently the
majority of women would probably not subject themselves to
an elective surgery purely for delaying menopause and it can
be argued whether or not any women would prefer to have
regular menstrual cycles up to 60 years of age, when readily
available pHRT compounds can deliver the hormones without
the bleeding. Nevertheless, OTC could potentially be justified
in some women already undergoing pelvic surgery for other
reasons for example, a Caesarean section or an appendectomy
where ovarian tissue could be collected and frozen as an adjunct.
This is, however, also an approach which is highly debatable and
may not be ethically and medically appropriate as no studies
have been conducted that directly or indirectly compare the
benefit and disadvantage of ovarian tissue removal for future
cHRT.
The group of women for whom the use of cHRT are most
likely to become a clinical option initially is the thousands
of women worldwide who have already had ovarian tissue
frozen for fertility preservation due to different malignancies
and genetic conditions. For various reasons, a large number of
these women will not have used their stored tissue by the time
they reach menopause, either prematurely or at the natural age
of menopause. Some of these women might wish to use their
store tissue for postponing menopause or to achieve natural
menopause which is nowadays recommended by many scientific
societies (8, 31). Studies have shown that women who become
postmenopausal before the age of 50 years and do not receive
any treatment have an increased risk for cardiovascular disease-
related mortality compared to women receiving pHRT (42–46).
Other studies have shown an almost doubled long-term risk of
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cognitive impairment or dementia in women who underwent
oophorectomy beforemenopause (47). A risk that was eliminated
if estrogen therapy was initiated after the surgery and continued
up to age 50 years or longer (47), which is advertising a need
for sustained ovarian function up to at least the age of natural
menopause.
However, many concerns and unanswered questions exist; Is
it safe? To whom is the risk-benefit profile actually favorable?
Are physiological hormones better than pharmaceutical? Careful
consideration of risks and benefits, individually structured
counseling and close monitoring are needed for each woman
who may want to use their ovarian tissue for primary prevention
or postponing menopause. To summarize, cHRT in the form
of stored ovarian tissue or ovarian cell constructs (41, 48, 49)
could potentially be used at the onset of natural or induced
menopause as an ideal time to institute preventative strategies
that could potentially increase the quality and length of women’s
lives. However, this is again technical possible but not proven in a
clinical setting with women in this age group, and it can be argued
that pHRT should be preferred in all cases as it is the cheapest
and simplest way to provide hormones, and no real evidence for
the superiority of physiological hormone levels exists. Therefore,
more research in the area of physiological and pharmacological
hormones is needed in order for this potential application to be
adopted clinically in the future.
OTC FOR NON-MEDICAL REASONS
In many countries women also have the opportunity to preserve
their fertility due to personal reasons and hereby postpone
childbearing. The increasing age of childbearing observed in
most high-income countries is often depicted as a result of
women selectively choosing to pursue a career and other life
goals before having children, however, evidence now suggests
that the primary reason is the lack of a partner who is willing
to commit to parenthood (50, 51). The traditional method of
fertility preservation for these social indications is vitrification of
mature oocytes. In recent studies, it has become evident that most
of the women who cryopreserve oocytes for non-medical reasons
are in their mid to late 30 s, well educated, socio-economically
advantaged and single (52–54). Data concerning the reproductive
experiences and outcomes of this growing group of women is still
very limited, but two severe issues with today’s policy for non-
medical oocyte freezing have emerged. First of all, women are
too old when they decide to store oocytes as the mean age at the
time of freezing is around 37 years (53, 55), whichmay be deemed
suboptimal (56). Additionally, one in five patients in this group
is a low responder and combined with the advanced maternal
age this results in one quarter of the women having fewer than
8–10 mature oocytes frozen which is considered necessary for a
reasonable chance of success (57). The second issue is that the
majority of the women with frozen oocytes do not come back
to collect them and the utilization rate of the stored oocytes
is currently below 10% (53, 55). Collectively, it appears that
especially reproductive aged womenmay only to a limited extend
benefit from this approach.
A proposition would be to use OTC as an alternative to
oocyte vitrification in connection with fertility preservation for
non-medical reasons. In contrast to mature oocytes, transplanted
ovarian tissue will give the woman the opportunity to conceive
spontaneously without IVF, which many women and their
potential future partners would probably appreciate. If the
woman ends up not needing the stored ovarian tissue for fertility,
then the tissue is not wasted, but could instead be used as
cHRT to alleviate postmenopausal symptoms later on or avoiding
POI. Thus, OTC may serve multiple purposes depending on
the need for either fertility or endocrine function and provide a
better justification of such intervention. In addition, by storing
ovarian tissue, and not just a fixed number of mature oocytes,
a range of potential new treatments, which are currently being
developed, might become available for these patients in the
future. These treatments include in vitro follicle activation (58),
culture of human preantral follicles (48, 59, 60), autologous
transfer of mitochondria to oocytes (61), and in vitromaturation
of immature oocytes (62).
OTC requires at least two surgical procedures to collect and
graft ovarian tissue and it might be overwhelming and excessive
for some patients. Therefore, OTC may only be a preferable
option over oocyte vitrification for some groups of patients in
particular women of advanced maternal age with a low ovarian
reserve or poor responders which require multiple cycles of
controlled ovarian stimulation. For these groups of patients, their
future use of stored ovarian tissue could potentially be enhanced
by in vitro follicle activation (IVA) in which the resting pool
of follicles is activated mechanically and/or biochemically prior
to transplantation. In 2013, Kawamura et al. were the first to
test IVA in a clinical setting and enabled POI patients without
menstrual cycles for several years to conceive with their own
oocytes by activating a residual pool of resting follicles (58). This
technique has so far resulted in three live births in Japan and two
pregnancies in other clinics (58, 63–65).
Taken together, oocyte cryopreservation is the clinical
available option for non-medical freezing, but it can be argued
that women seeking fertility preservation for non-medical
reasons should be presented with both fertility preserving options
and the potential beneficial applications for cHRT and future
use, and then the woman can help decide which method is most
suitable for her. It should be highlighted that age is the most
limiting and critical factor for both methods, and the success
rate always depends hereof, which means that the issue with low
ovarian reserve will apply for both methods, and low return rates
are probably an inevitable factor in this group of women.
A MODERN OVARIAN RESECTION FOR
ANOVULATORY PCOS WOMEN
A completely new way of utilizing OTC is in the context
of surgical treatment for anovulatory women with polycystic
ovaries. Polycystic ovary syndrome (PCOS) is one of the
most common endocrine disorders among women in their
reproductive age and is a predominant cause of anovulatory
infertility. In 1930s, Stein and Leventhal developed the ovarian
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wedge resection (OWR) in which the ovarian volume was
surgically reduced during laparotomy (66). For decades OWR
was the only treatment for PCOS as it effectively restored regular
menstrual cyclicity for a period of time in 80–90% of women
with PCOS and allowed conception in 45–65% of those who
underwent surgery (66). However, the procedure later became
less popular due to significant side effects; primarily a significant
incidence of postoperative pelvic adhesion formation adding
to the infertility-issue (67–69). Furthermore, follow-up studies
revealed that OWR was not always curative and a significant
number of women, 30–35%, reverted into a state of anovulation
or oligo-ovulation (69, 70). With the introduction of clomiphene
citrate (CC) and human menopausal gonadotropins in the 1960s
the surgical treatment of PCOS was less used, and today CC
is used as the first-line therapy for ovulation induction in
women with anovulatory PCOS (71, 72). However, 10–15%
of women are CC-resistant and will not ovulate in response
to CC, and in those who do respond, not all will conceive.
Laparoscopic ovarian drilling (LOD) using a unipolar electrode
is currently recommended as a successful second-line treatment
for ovulation induction in women with CC-resistant PCOS,
as it has been shown to be just as effective as gonadotropin
treatment, but less expensive and not associated with an increased
risk of multiple pregnancy, ovarian hyperstimulation syndrome
(OHSS) or pregnancy loss (71, 73–75). In the 1980’s the
first studies on LOD showed that ovulation was restored in
92% of patients, with a pregnancy rate of up to 80% (76).
Furthermore LOD allows multiple attempts of conception,
but without intensive monitoring, and is preferred by the
majority of patients (75). The main shortcomings of LOD
are postoperative adhesion formations and the potential risk
of affecting the ovarian reserve in case of excessive damage
(75).
We therefore hypothesize that the development of a modern
version of an ovarian resection in which ovarian biopsies are
excised surgically during laparoscopy and subsequently frozen
could potentially provide an alternative to traditional LOD and
OWR in CC-resistant women with PCOS. In this case, the
surgical intervention should be performed in a way in which
whole pieces of cortical and medullary tissue is removed in
amounts similar to what is destroyed during LOD, and the
ovarian cortex could then be isolated and frozen to preserve
the follicles for potential later use instead of wasting them when
performing LOD or OWR. Thus, in cases were too much tissue is
removed during the surgical procedure the stored ovarian tissue
can be grafted as back-up, or potentially be used for cHRT if
the patient later on enters menopause prematurely or for fertility
at an advanced reproductive age. In 1970’s it was incidentally
noted that ovarian biopsy alone (taken for diagnostic purposes)
could induce regular menstrual cyclicity and conception in some
women with PCOS (77), and in 1980’s OWR was also performed
through multiple ovarian biopsies and reported successful using
a laparoscopic approach with less adhesion formations (78).
Like LOD the proposed modern version of an ovarian resection
through excision of ovarian biopsies would restore regular
ovulation and allow spontaneous pregnancy, and in patients
who remain anovulatory following the procedure most of them
would have an increased responsiveness of the ovary to CC-
treatment or respond less aggressively to exogenous hormone
stimulation. Taken together, the proposed procedure using OTC
to advance a surgical treatment for PCOS patients is completely
theoretical and has not been tested in a clinical setting, however,
this approach could potentially utilize the excessive—and in this
case harmful—follicle pool in a beneficial way by relieving PCOS
symptoms immediately and at the same time securing ovarian
endocrine function later on in life. The efficacy and advantages of
the proposed procedure now needs to be proven and compared to
LOD in a clinical setting to justify any potential use in the future.
OPTIMIZING CULTURE SYSTEMS FOR
IMMATURE OOCYTES
By freezing ovarian cortical tissue for fertility preservation, it
is possible to gain access to a wide range of immature oocytes,
including early preantral and small antral stage follicles, which
can be isolated and collected from surplus or donated ovarian
tissues (62, 79). This provides a rare opportunity to characterize
the basic molecular mechanisms controlling and regulating
human follicular growth and maturation in unstimulated ovaries
of fertile women (80, 81), and to develop and optimize culture
conditions for immature oocytes (59, 62), which could provide
additional fertility for young women with a wide range of
indications. Thus, utilization of immature oocytes could in this
way augment the overall fertility from the OTC procedure.
Moreover, young cancer survivors with a risk of ovarian
involvement from the underlying cancer cannot have their
stored ovarian tissue transplanted safely, and current advances in
culture systems for the earliest stages of follicles could potentially
provide fertility for these women in the future. In a recent
paper, Telfer et al. succeeded with in vitro growth of unilaminar
follicles (IVG) in a multi-step culture model which supported
the development and maturation to the Metaphase II stage
(60).
Several studies have now shown that a considerable number
of immature oocytes can be collected from small antral follicles
visible on the surface of the ovary or released to the dissection
medium during the preparation for OTC (62, 82–84). These
oocytes can be matured, vitrified and used to augment fertility
to the patient (62, 84–86). The maturation rate has been shown
to vary between ∼30 and 60% (87), and the first three live births
resulting from a cryopreserved embryo obtained from in vitro
matured (IVM) oocytes has been reported (82, 88, 89). However,
there is plenty of room for improvement and currently IVM
is mainly used as an additional fertility preserving option in
combination with OTC or to avoid OHSS in PCOS patient. A
more widely use of IVM is currently not accepted due to the
fact that implantation and developmental potential of embryos
derived from IVM oocytes has consistently been reported to be
significantly lower in comparison to in vivo matured oocytes
(90, 91).
One explanation for the inefficiency of IVM is that IVM
protocols have changed little, if any, since the first reported
birth obtained by IVM oocytes in 1994 using a non-specific
Frontiers in Endocrinology | www.frontiersin.org 6 June 2018 | Volume 9 | Article 347
Kristensen and Andersen OTC-More Than Just Fertility Preservation
medium (MEM) with addition of FSH, LH and estradiol as
hormones and maternal serum as supplements (92). In recent
reports, commercial maturation media have been used for
IVM in both patients with PCOS and women undergoing
fertility preservation, but there is no real evidence that the
formula is appropriate for oocyte maturation in vitro (91).
Thus, IVM in connection with OTC provides a unique
platform to compare multiple culture media compositions
and improve basal maturation conditions for IVM. Another
explanation for the decreased implantation and pregnancy
rate with the use of IVM derived embryos is insufficient
endometrial receptivity. The limited time between oocyte
recovery and embryo transfer is potentially insufficient to allow
full completion of the endometrial proliferative phase, which
could compromise the formation of a secretory endometrium
and the chances of embryonic implantation (91). A study by
De Vos et al. has shown that implantation and pregnancy
rates were much higher in replacement cycles using frozen
embryos obtained after IVM compared to cycles in which
embryos were transferred fresh after IVM (93). Thus, the
relatively lower clinical efficiency that currently characterizes
IVM might derive not exclusively from reduced oocyte quality
caused by inadequate IVM conditions, but also from inadequate
endometrial receptivity. Therefore, the notion that IVM oocytes
are intrinsically less developmentally competent will need to be
reconsidered.
Despite the current limitations, IVM continue to attract
growing interest in consideration of potential novel applications
in human ART. However, to advance more sophisticated IVM
systems able to reproducemore physiologically and efficiently the
process of oocyte maturation, we need more research material
and settings such as provided by OTC, in which we can gain a
better understanding of the biological mechanisms transforming
a fully-grown oocyte into a mature fertilizable gamete.
CONCLUSION
OTC in prepubertal girls and young women is becoming an
increasingly well-established method of fertility preservation in
many clinics worldwide. However, by storing ovarian tissue
more than just the reproductive potential is preserved. The
steroidogenic capacity and endocrine function of the tissue could
potentially expand the utilization of OTC and the ovarian reserve
to other beneficial applications throughout the female lifespan
and several indications beyond cancer. With an increasing
prevalence in loss of ovarian function due to POI and aging
we now need to explore these opportunities and outweigh the
cost-benefit and risk-benefit ratios associated with potential
new treatments. Nonetheless, it is important to recognize that
fertility and endocrine function restored with ovarian tissue
go hand in hand and that both are the result of follicular
activity.
In conclusion, the described and suggested applications for
OTC in this review are technically possible, however they
have not been validated clinically (with the exception of
puberty induction), and therefore the suggested applications
should be regarded as an optimistic view on the potential
future use of OTC. Moreover, the suggested applications
for OTC are thought provoking to many people and the
controversial opinions hereof should of course be recognized.
Finally, the burden of repeated surgical interventions in
connection with OTC must in all cases be weighed against the
simple, cheap, and readily available pHRT medications which
already exist and are administered to millions of women
worldwide.
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